

Lorraine V Kalia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6885550/publications.pdf>

Version: 2024-02-01

64
papers

9,400
citations

159525

30
h-index

128225

60
g-index

65
all docs

65
docs citations

65
times ranked

13516
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinson's disease. <i>Lancet, The</i> , 2015, 386, 896-912.	6.3	4,079
2	Src kinases: a hub for NMDA receptor regulation. <i>Nature Reviews Neuroscience</i> , 2004, 5, 317-328.	4.9	692
3	Glycine binding primes NMDA receptor internalization. <i>Nature</i> , 2003, 422, 302-307.	13.7	382
4	NMDA receptors in clinical neurology: excitatory times ahead. <i>Lancet Neurology, The</i> , 2008, 7, 742-755.	4.9	363
5	Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2626-2631.	3.3	342
6	Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.	4.9	279
7	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	4.5	272
8	α -Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	2.8	255
9	Tyrosine Phosphatase STEP Is a Tonic Brake on Induction of Long-Term Potentiation. <i>Neuron</i> , 2002, 34, 127-138.	3.8	196
10	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.	2.2	188
11	Severity of chronic pain and its relationship to quality of life in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 322-327.	1.4	176
12	Animal models of α -synucleinopathy for Parkinson disease drug development. <i>Nature Reviews Neuroscience</i> , 2017, 18, 515-529.	4.9	166
13	Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. <i>Nature Medicine</i> , 2011, 17, 470-478.	15.2	157
14	Neto1 Is a Novel CUB-Domain NMDA Receptor-Interacting Protein Required for Synaptic Plasticity and Learning. <i>PLoS Biology</i> , 2009, 7, e1000041.	2.6	150
15	Src in synaptic transmission and plasticity. <i>Oncogene</i> , 2004, 23, 8007-8016.	2.6	146
16	α -Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.	4.2	120
17	Ubiquitinylation of α -Synuclein by Carboxyl Terminus Hsp70-Interacting Protein (CHIP) Is Regulated by Bcl-2-Associated Athanogene 5 (BAG5). <i>PLoS ONE</i> , 2011, 6, e14695.	1.1	119
18	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. <i>Neurotherapeutics</i> , 2014, 11, 6-23.	2.1	119

#	ARTICLE	IF	CITATIONS
19	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.5	103
20	Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. <i>Movement Disorders</i> , 2013, 28, 131-144.	2.2	99
21	Interactions between Src family protein tyrosine kinases and PSD-95. <i>Neuropharmacology</i> , 2003, 45, 720-728.	2.0	92
22	Differential Frequency Dependence of P2Y1- and P2Y2- Mediated Ca ²⁺ Signaling in Astrocytes. <i>Journal of Neuroscience</i> , 2003, 23, 4437-4444.	1.7	81
23	Î±-Synuclein and Lewy pathology in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2015, 28, 375-381.	1.8	79
24	Î±-Synuclein and Parkinsonism: Updates and Future Perspectives. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 31.	2.0	69
25	Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by Î±-synuclein. <i>Acta Neuropathologica Communications</i> , 2020, 8, 17.	2.4	65
26	PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. <i>EMBO Journal</i> , 2006, 25, 4971-4982.	3.5	56
27	Deep brain stimulation: potential for neuroprotection. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 174-185.	1.7	50
28	Direct detection of alpha synuclein oligomers in vivo. <i>Acta Neuropathologica Communications</i> , 2013, 1, 6.	2.4	49
29	LRRK2 and Î±-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?. <i>Frontiers in Neuroscience</i> , 2020, 14, 577.	1.4	49
30	Biomarkers for cognitive dysfunction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S19-S23.	1.1	37
31	Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 1-11.	0.6	32
32	Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death. <i>Cell Death and Disease</i> , 2019, 10, 907.	2.7	32
33	Recent Advances in the Development of Stem Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1772-1780.	2.2	31
34	Parkinsonism due to A53E Î±-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. <i>Movement Disorders</i> , 2018, 33, 1950-1955.	2.2	25
35	Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: An open label case series. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 407-412.	1.1	22
36	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 864-872.	0.9	22

#	ARTICLE	IF	CITATIONS
37	COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8.	1.5	21
38	The eIF2 γ kinase HRI triggers the autophagic clearance of cytosolic protein aggregates. <i>Journal of Biological Chemistry</i> , 2021, 296, 100050.	1.6	21
39	Diagnostic biomarkers for Parkinson's disease: focus on α -synuclein in cerebrospinal fluid. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 21-25.	1.1	16
40	Merging DBS with viral vector or stem cell implantation: a hybrid stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 15051.	1.8	14
41	Emerging disease-modifying strategies targeting α -synuclein for the treatment of Parkinson's disease. <i>British Journal of Pharmacology</i> , 2018, 175, 3080-3089.	2.7	13
42	Methods for detecting toxic α -synuclein species as a biomarker for Parkinson's disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 291-307.	2.7	13
43	Small molecule inhibitors of α -synuclein oligomers identified by targeting early dopamine-mediated motor impairment in <i>C. elegans</i> . <i>Molecular Neurodegeneration</i> , 2021, 16, 77.	4.4	13
44	Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. <i>Pharmacoeconomics and Drug Safety</i> , 2021, 30, 201-209.	0.9	11
45	Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease. <i>Journal of Neurosurgery</i> , 2020, 135, 273-278.	0.9	10
46	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2012, 78, 838-838.	1.5	9
47	C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. <i>Current Neuropharmacology</i> , 2021, 19, 1038-1068.	1.4	9
48	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 165-171.	1.1	7
49	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 76-78.	0.8	6
50	Is there a role for MR-guided focused ultrasound in Parkinson's disease?. <i>Movement Disorders</i> , 2018, 33, 575-579.	2.2	6
51	BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 716.	1.8	6
52	Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members. <i>Neural Regeneration Research</i> , 2021, 16, 684.	1.6	6
53	Thoracic Myelopathy from Coincident Fluorosis and Epidural Lipomatosis. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 276-278.	0.3	5
54	[¹⁸ F]AV-1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , 2018, 33, 1360-1361.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus. <i>Frontiers in Neuroscience</i> , 2020, 14, 463.	1.4	4
56	Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease". <i>Parkinsonism and Related Disorders</i> , 2020, 74, 78-79.	1.1	3
57	Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	3
58	Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. <i>Neurology: Genetics</i> , 2021, 7, e600.	0.9	3
59	Complex genomic rearrangement in <i>SPG11</i> due to a DNA replication-based mechanism. <i>Movement Disorders</i> , 2017, 32, 1792-1794.	2.2	1
60	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-5.	0.3	1
61	Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. <i>Movement Disorders</i> , 2017, 32, 106-106.	2.2	0
62	Multiple system atrophy and myoclonus. <i>Neurology</i> , 2019, 93, 287-288.	1.5	0
63	An Intelligent Diagnosis: SMART Syndrome. <i>American Journal of Medicine</i> , 2021, 134, 863-865.	0.6	0
64	A New Chapter for the Journal of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1365-1367.	1.5	0